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Abstract
Background: The prevalence of obesity with aging is escalating alarmingly; and pelvic organ prolapse (POP) and
stress urinary incontinence (SUI) are now becoming a growing epidemic among the elderly. Synthetic transvaginal
mesh has been employed with increasing popularity in the treatment of POP and is usually highly effective in controlling
the principal symptoms of prolapse. However, studies have reported that mesh operations provide fairly unfavorable SUI
cure rates. Therefore, additional anti-incontinence surgical strategies are increasingly being scrutinized to achieve better
postoperative continence without any significant side-effects for patients with both POP and SUI. We hypothesize that
the modification with the fixing of the mesh to the mid-urethra is superior to the original transvaginal mesh operation
(TVM) with regard to anti-incontinence.
Methods: One hundred and thirty patients diagnosed with POP–Q II–III and concomitant SUI requiring surgical
treatment will be included in this prospective, randomized, double-blind, controlled clinical trial. Patients will be
randomly allocated to receive either original TVM (TVM group, n = 65) or modified TVM surgery (mTVM group, n= 65). As
the primary outcome parameter, we will evaluate the objective SUI and POP cure rates. Secondary endpoints include
postoperative morbidity as assessed with the International Urogynaecological Association classification and subjective
prolapse and incontinence cure rates reported by questionnaires.
Discussion: Recognizing the importance of an additional surgical procedure for anti-incontinence management, we aim
to investigate whether a stabilizing suturing of the mesh to the mid-urethra delivers superior SUI correction compared to
the original prosthesis surgery.
Trial registration: ClinicalTrials.gov, NCT02935803. Registered on 20 May 2016.
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Background
Demand for pelvic organ prolapse (POP) and stress urin-
ary incontinence (SUI) surgery is expected to increase due
to an expanding rate of obesity among elderly women.
POP is defined as the protrusion of the pelvic organs from
the normal anatomical location toward or through the va-
ginal opening; the current prevalence of symptomatic POP
is in the range of 3–8% [1, 2]. SUI, classified as involuntary
loss of urine during physical activities and a resultant in-
crease in intra-abdominal pressure, is also highly prevalent,
reaching as high as 24.8% [3].
Also of note, one-fifth of women in the United States re-
ceives surgery either for SUI or for POP [4], where the cu-
mulative risk for SUI surgery is 13.6% and that for POP
surgery is 12.6% [4]. Both pathologic conditions develop
in > 50% of the women affected [5]. Synthetic transvaginal
mesh (TVM) has been increasingly employed in the treat-
ment of POP and tension-free slings are useful in the man-
agement of incontinence. Synthetic mesh during repair has
principally been used due to higher efficacy compared to
that of native tissue repair and resorbable mesh; however,
complications appear to be more prevalent [6–9]. Com-
mon complications include mesh extrusion, chronic pelvic
pain, dyspareunia, and infection [7–10]. The anti-SUI effi-
cacy of the prosthetic placement is barely 72–83% [11–13];
however, it is assumed that a combination of a synthetic
mesh with the sling operation [5, 14–16] will substantially
increase the cure rate for concomitant SUI.
Despite the increased consideration of the combined
surgery for both genitourinary pathologies in one ses-
sion, there is a lack of consensus on the optimal treat-
ment. It is supposed that a combined operation with
mesh and sling is highly effective for the treatment of
POP and SUI; however, the complication rate is elevated
[5, 14–16].
Therefore, the research group developed a modifica-
tion to the transobturator four-arm TVM [13, 17] to in-
crease its anti-incontinence effect. While the sling is
located beneath the mid-urethra, the TVM elevates the
distal part of the anterior vaginal wall [13, 17]. In the
original TVM, the posterior part of the mesh is
anchored to the anterior aspect of the cervix and the
anterior arms are spread under the bladder neck with
stabilizing sutures. We hypothesize that the original
TVM operation can be followed by residual SUI since
the strengthening of the back arms may result in a back-
ward dislocation of the entire mesh. The posterior
movement of the mesh allows the dorsal rotation of the
urethra since the mid-urethra is not suspended. The
proposed modification to the original surgical procedure
includes the suture of the anterior part of the mesh to
the mid-urethra to prevent the mesh sliding. We think
that the appropriate elevation of the mid-urethra would
thus occur with the anterior arms and that would
achieve a more effective anti-incontinence. The pubour-
ethral ligament is usually loose in SUI, but the anchored
mesh would theoretically normalize its function and
stabilize the urethra. Intra- and postoperative complica-
tion rates would be expected to be similar to those with
the original four-arm TVM, but the modified TVM with
the anchoring suture would be slightly superior with re-
spect to POP repair and remarkably more effective in
SUI correction. In our preliminary study, the anterior
fixing of the TVM to the mid-urethra demonstrates as
high an efficacy of anti-incontinence as 96.8% and an
enormously reduced recurrence prolapse rate of 3.2% in
(unpublished data). The mesh extrusion rate is particu-
larly low and this may be due to the fact that the stabil-
izing sutures exert a lack of “folding/wrinkling” of the
edge of the mesh, preventing a lifting up of the mesh
which does not compress the mucosa and derange the
periprosthetic vasculature.
A further modification to the TVM surgery is that the
positioning of the mesh will occur 1.5 cm below the
urethral meatus, leading to an elevation of the entire
anterior vaginal wall including the anterior and middle
compartments as well. By contrast, the original TVM
surgery does not prevent anterior compartment prolapse
[13, 17].
Methods/design
Study design
The present study is a single-center, prospective, double-
blind (participant, investigator/surgeon, outcome assessor),
randomized, controlled trial. The study will be conducted
in accordance with the Declaration of Helsinki and has
been approved by the local medical ethics committee at
the University of Szeged under reference number 55/2016.
The trial is registered under NCT 02935803, and patient
recruitment started on 22 August 2016. The trial flow
diagram is presented in Fig. 1 (CONSORT study flow dia-
gram). The protocol follows the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
checklist (see Additional file 1).
Patient recruitment and consent procedure
Patients will be recruited from the urogynecology con-
sultation at the Division of Urogynaecology, Department
of Obstetrics and Gynaecology, University of Szeged,
Hungary. All study participants will be provided an in-
formation sheet and a consent form describing the study
in brief so they can decide whether to participate in the
study. Each participant will be explicitly informed that
participation in the study is voluntary, that she may
withdraw from the study at any time and that with-
drawal of consent will not affect her subsequent medical
assistance and treatment.
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Consent to publish Written informed consent was
obtained from the patients for publication of their indi-
vidual details and accompanying images in this manu-
script. The consent form is held by the authors in the
patients’ clinical notes and is available for review by the
Editor-in-Chief.
Participants considered for trial
This will be a prospective longitudinal study involving
all patients successively scheduled for operation for
symptomatic prolapse POP–Q grade II or III and
coexisting SUI, who will be included in the study after
informed consent has been obtained. Patients will be
recruited in the Department of Obstetrics and Gynaecol-
ogy at the University of Szeged. The study will be con-
ducted for an estimated maximum of 18 months
(between August 2016 and December 2017). Table 1
provides an overview of the patient recruitment and
evaluation plan.
The symptomatic POP–Q Stage II–III (determined by
the gynecological examination using the International
Continence Society quantification system) [18] anterior
vaginal wall prolapse is defined as the maximum extent
of the prolapsed anterior and middle compartments
being within 1 cm above and 6 cm below the hymen [19,
20]. According to the international POP guidelines (the
EBU and NICE guidelines) [21, 22], if the condition
disrupts the patient’s life and non-surgical treatment
options have not helped, it should be treated surgically.
In all cases, SUI will be visualized after a complete
physical examination is performed (verified by pad test/
Bonney test/two-dimensional [2D] introital sonography
and urodynamic examination). The severity of SUI was
assessed using the Ingelman–Sundberg classification
[23]. Urodynamic examinations comprising uroflowme-
try, cystometrography, the pressure-flow study, and the
abdominal leak point pressure test will be performed be-
fore surgery to objectively determine the coexisting
symptomatic SUI based on the international guidelines
(the EBU and NICE guidelines) [21, 22]. The abdominal
leak point pressure test will be used as a standardized
examination method for the evaluation of SUI with urine
leakage as a sign. If the intra-abdominal pressure re-
corded at the point of urine leakage was < 40 cmH2O,
the origin of the SUI was set as intrinsic sphincter defi-
ciency (ISD) [24]. In the case of ISD, preoperative pelvic
floor training (PFMT) will be recommended. If the pa-
tient is unwilling to participate in PFMT or if the
Enrollment
Women requiring surgery for POP and coexistin SUI
Assessed for eligibility by urogynaecologist Exclusion
Declined to participate
Not meeting inclusion criteria
OtherBaseline assessment
Randomization
Do not wish to be randomized
Allocation
Lost after randomization
Modified 
transvaginal mesh 
surgery 
(mTVM) (n=89)
Original 
transvaginal mesh 
surgery 
(TVM) (n=89)
Postoperative (6 weeks, 6 
weeks, 6 months, 1 year, 2 
years) assessment
All outcomes
Postoperative (6 weeks, 6 
weeks, 6 months, 1 year, 2 
years) assessment:
All outcomes
Follow-up
Lost to follow-up
Discontinued intervention
(n=16)
Lost to follow-up
Discontinued intervention
(n=16)
3 years after surgery
Assessment: all outcomes
Analysed (n=65)
3 years after surgery
Assessment: all outcomes
Analysed (n=65)
Analysis
Fig. 1 CONSORT study flow diagram
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training was unsuccessful, we will recommend mesh
surgery. This will also be the case for suspected urethral
hypermobility, i.e. if the intra-abdominal pressure at the
point of urine leakage was > 60 cmH2O.
Introital ultrasound findings
In all cases, introital ultrasound (GE Voluson 730) will
be performed with a standardized bladder-filling volume
of 300 mL. The vaginal probe (5–9 MHz) will be placed
in the area of the vaginal introitus at the level of the ex-
ternal urethral orifice, with the patient in a semi-sitting
position. Ultrasound assessment of the bladder and
urethra starts in the mid-sagittal plane.
During the sonography, we measure the longitudinal
(L) distance between the bladder neck and the line
through the lower edge of the pubic symphysis and the
horizontal (H) distance between the bladder neck and
the upper edge of the symphysis. The two distances are
measured at rest (L1, H1), during contraction (L2, H2),
on pressing or while coughing (L3, H3). Changes in
these parameters during contraction of the levator
muscle and on pressing serve to evaluate the reactivity
of the pelvic floor muscles and the adequacy of the
supportive structures of the urogenital organs [25]. The
funneling of the proximal urethra during coughing as a
typical stress urinary sign also will be examined [25].
Inclusion and exclusion criteria
Inclusion criteria
Female adults aged > 40 years with coexisting pelvic floor
defects will be recruited, at least one year following de-
livery, irrespective of parity and pre- or postmenopausal
state, medically and physically fit for the measurement
and therapeutic surgeries, and, in the case of systemic or
local estrogen treatment, stable for the past three
months before inclusion.
Exclusion criteria
Exclusion criteria are: urge, mixed incontinence or occult
SUI; prolapse < grade II or > grade III POP–Q ([21, 22],
https://uroweb.org/guideline/urinary-incontinence), apical
or posterior compartment prolapse, dysuria (bladder
tumor, neurogenic urinary bladder damage), a history of
mesh use or anti-incontinence pelvic procedures; preg-
nancy (urine test to accomplish); lactation period not yet
finished; current urinary tract or vaginal infection, men-
struation on the day of examination; contraindications for
measurements or interventions, for example, acute inflam-
matory or infectious disease, tumor or fracture; de novo
systemic or local estrogen treatment (< 3 months); de novo
drug treatment with anticholinergics or other bladder ac-
tive substances (tricyclic antidepressants and selective sero-
tonin reuptake inhibitors) and cancer of the pelvic organs.
Concealment of group allocation from participants
After the screening phase, patients will be randomly
assigned to one of the two therapy groups (the TVM
group or modified TVM (mTVM) group). The alloca-
tion sequence will be generated by the independent uro-
gynecology secretariat using online randomization
software (http://randomization.com); allocation ratio =
1:1 (TVM group:mTVM group). The allocation will be
concealed in sealed, opaque, sequentially numbered en-
velopes, which will be stored at the operating theatre.
All the women recruited will be numbered consecutively
corresponding to the numbered envelopes. The envelope
will not be opened until the general narcosis of the study
participant has been established. To increase the validity
of the trial, the assigned procedure will be blinded for
the study participants throughout the follow-up period.
The participants will be informed of allocated treatment
after completing the study forms 12 months after the
procedures. If major complications occur, the study par-
ticipants and the outcome assessor will be also informed
Table 1 Schedule of assessments/data collection
Assessment Recruitment
before
intervention
phase
Intervention
(surgery)
Follow-up
6 weeks 6 months 1 years 2 years 3 years
Assessment of eligibility criteria x
Written informed consent x
Gynecological examination: incontinence symptoms x x x x x x x
Gynecological examination: prolapse x x x x x x x
Urodynamic examination x x x
Adverse events x x x x x x
Questionnaires: PISQ-12 and PFDI x x x x x x
Introital sonography x x x
Urine culture x x x x x
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of the allocated treatment at the time of any suspected
complication(s).
Randomization
The patients will be randomized to one of the study
groups using a computer-generated list. Allocation con-
cealment will be ensured by enclosing assignments in
sealed, opaque, sequentially numbered envelopes, which
will only be opened when the general narcosis of the
study patient has been established [26].
Postoperative outcomes and sequalae will be assessed
by an outcome assessor who is a gynecologist in a sub-
specialization program in urogynecology and also well
trained in the transvaginal mesh operation. The outcome
assessor will remain blinded to the type of intervention
throughout the study.
Blinding
Participants will be blinded against the type of TVM sur-
gery received (original TVM vs mTVM). The participant
information document will not provide any information
on the differences in surgical protocols such that the
women could ascertain their group allocation. All inves-
tigators involved in data acquisition, data analyses, and
statistics will also be blinded against group allocation.
The surgeons in charge of the therapy cannot be blinded
against group allocation and therefore will not be in-
volved in data acquisition, data reduction, data analyses,
or statistics.
Measurement outcomes
Baseline (before intervention phase) and follow-up mea-
surements (of primary, secondary, and tertiary out-
comes) after six weeks to three years will be performed
at the Division of Urogynaecology, Department of Ob-
stetrics and Gynaecology, University of Szeged, Hungary,
by an experienced urogynecologist who will be blinded
to group allocation of participants and who will not
operate on the patients (Table 1).
Primary endpoints
The primary outcome measures will be a significant im-
provement in POP repair and objective cure of SUI after
the surgery. The efficacy of POP repair will be under-
stood as a significant (> 3 cm) improvement during
follow-up at points Aa, Ba, C, and D using the POP–Q
system (International Continence Society) [19, 20]. Anti-
incontinence efficacy is classified as no further SUI, as
diagnosed by cough tests and urodynamic examinations.
Besides the gynecological and urodynamic examinations,
sonographic findings from introital ultrasound examina-
tions will be analyzed in terms of anatomical success
both before and following surgery and during follow-up.
Secondary and tertiary endpoints
The secondary measurement outcome will comprise the
intraoperative findings and postoperative factors. As con-
cerns the long-term postoperative complications of the
mesh procedures, we will determine the extrusion rate,
the presence of de novo urge symptoms (DNUS) or urin-
ary tract infection (UTI), and the need for reoperation.
The diagnosis of DNUS will be set if detrusor pressure
changes are detected in cystometrographic pressures after
the surgeries. The postoperative complications that will
lead to reoperation will be infection, recurrent descent or
incontinence, implant extrusion, chronic pelvic pain, and
total retention. Operative and perioperative complications
(six weeks after the procedures) described after TVM vs
mTVM will be collected; overall frequency within all the
cases will be calculated and severity will be graded using
the IUGA classification comprising all the follow-up
periods [27].
The subjective cure for prolapse and incontinence will
be measured with a significant enhancement of the Pel-
vic Organ Prolapse/Urinary Incontinence Sexual Ques-
tionnaire (PISQ-12) and Pelvic Floor Distress Inventory
(PFDI) scores. The PISQ-12 and PFDI are validated to
assess the impact of SUI symptoms on quality of life and
sexuality and relate well to the prolapse symptoms. Pre-
vious research has demonstrated that the questionnaires
correspond well with grade of prolapse and urodynamic
findings [5, 13, 17]. Our research group has assessed the
validity of the questionnaires in screening for subjective
genitourinary symptoms (unpublished data). To guaran-
tee blinding of the tertiary outcome, the participant will
complete the questionnaire without the outcome asses-
sor present and seal it in an envelope, which will be
given to research staff. The subjective outcome assess-
ment is largely performed by participant-completed
questionnaire, thus avoiding interviewer bias.
Trial interventions
Participants will receive the allocated intervention, either
the original TVM operation or mTVM surgery. The sur-
gical interventions will be delivered by two surgeons
with expertise in the specific intervention and subspecia-
lized in urogynecology. They will not assess the meas-
urement outcomes. Further details on the interventions
are provided below.
Original transobturator four-arm transvaginal mesh
Original transvaginal subvesical mesh operations will be
performed as described earlier by Sergent et al. [13, 17].
The operative technique is described in detail in another
study [28]. The routine surgical technique will consist of
a longitudinal incision of the anterior vaginal wall
throughout its thickness from 3 cm below the urethral
meatus to the cervix. The posterior part of the mesh will
Fekete et al. Trials  (2017) 18:624 Page 5 of 8
be anchored to the anterior side of the cervix using two
non-absorbable Prolene® 2-0 sutures (Ethicon, Issy-les-
Moulineaux, France), while the mesh will then be spread
by securing its anterior parts beneath the bladder neck
using two or three Monocryl® 2-0 absorbable sutures
(Ethicon, Issy-les-Moulineaux, France). Conventional in-
struments will be employed for the original TVM
procedure.
Modified intervention surgery
In the modified surgical technique, the prosthesis is
placed between 1.5 cm below the urethral meatus and
the cervix and the anterior part of the mesh is anchored
with a stabilizing suture to the periurethral tissue at the
level of the mid-urethra to elevate the middle part of the
urethra, leading to potentially more effective anti-
incontinence. An additional document file presents the
intervention (detailed description of the mTVM) in
detail (see Additional file 2).
Assessment of safety: postoperative complications/
reoperations
In the current study, there are no anticipated risks or in-
conveniences, as the examinations and intervention
employed are well-known and widely used in pelvic floor
defect surgery. The modification to the TVM surgery
does not carry a higher risk for patients than that of the
original TVM in the setting of a fully equipped oper-
ation theatre. This makes the immediate detection and
treatment of adverse events possible. Also, after leaving
the operation room, all patients will be closely moni-
tored for the occurrence of potential (severe) adverse
events (short-term postoperative complications) on the
postoperative intensive ward. Moreover, the inclusion of
each individual patient in the study is indicated in the
electronic hospital information system and, hence, is
visible to all physicians and nurses involved in the care
of the patient. This facilitates the reporting of (severe)
adverse events to the principal investigator. The princi-
pal investigator will report suspected unexpected serious
adverse reactions to the Institutional Review Board.
Statistical methods
Hypothesis
Alternative hypothesis for primary outcome: it is hy-
pothesized that the group undergoing the modified
transvaginal mesh operation will have a statistically
higher improvement of continence measured by
gynecological and urodynamic examination, and from
the questionnaire administered before and after the
intervention phase.
Sample size calculation
As we have newly developed the modification to the
prosthesis surgery, an exploratory pilot study was de-
signed to evaluate the feasibility of the modification to
the mesh for the treatment of SUI. Twenty patients with
SUI and POP were recruited for a mTVM operation by
the same two senior surgeons who are conducting this
randomization study. The sample size calculation study
was designed based on preliminary data on the 20
patients. The newly developed technique yielded an ob-
jective SUI cure rate of 92% as opposed to 72% for the
original TVM published by Sergent et al. [13, 17].
Sample size calculations were performed with G*Power
software [29], using the statistical model for an χ2
approach. Consequently, sample size was estimated the-
oretically and an effect size of = 0.1, indicating a small
effect, will be accepted. The sample size was calculated
for the primary outcome of the SUI cure rate with the
following assumptions: α = 0.05, power (1–β error prob-
ability) = 0.8, number of groups = 2. Based on these as-
sumptions, a total sample size of N = 130 was estimated.
In anticipation of dropouts (10%: n = 16) or a violation
of protocol (10%: n = 16), a final sample size of N = 162
(81 participants per group) results.
Statistical analyses
Analysis of the patients will follow the CONSORT flow
diagram (Fig. 1) through the phases of the study (enroll-
ment [assessed, excluded, randomized], allocation [con-
trol group and experimental group with intervention
received or not received], follow-up [lost to follow-up,
discontinued intervention] and analysis) [30].
All statistical analyses will be conducted using SPSS
software version 22 (IBM, Armonk, NY, USA). All tests
will be two-sided and significance will be set at P < 0.05.
Efficacy measurements were adjusted by intention-to-
treat analysis. Missing values will be replaced using the
last observation carried forward (LOCF) method. No
subgroup analyses are planned. Standard deviations, 95%
confidence intervals, and median will be used for the de-
scriptive analyses. Primary and secondary outcome ana-
lysis: the Chi-square test or Fisher’s exact test will be
employed to identify any objective outcome differences
among groups.
Generally, continuous data will be checked for normal-
ity using the Shapiro–Wilk test. If the normality
assumption is violated, then PISQ-12 and PFDI scores as
tertiary outcomes will be normalized by log transform-
ation (log10(x)). Univariate-repeated measure analysis of
variance (ANOVA) will be used to determine the
secondary outcome between and within the two groups
(mTVM, TVM group) at six endpoints (before interven-
tion and during follow-up clinical appointments 1–5
following intervention). Mixed design ANOVA will be
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carried out to determine the effects of the modified
operation on subjective cure rate for POP and SUI, and
the Bonferroni post hoc test will be used to test the dif-
ference between means. All statistical analyses will be
completed after the final measurement of the last patient
during the last clinical appointment after intervention.
The repeated measure design with seven points in time
allows us to monitor how patients change over time in
both short-term (before/during intervention) and long-
term situations (before/after intervention).
Discussion
Coexisting POP and SUI are increasingly recognized as a
major health and financial concern affecting 63–80% of
postmenopausal women [31]. TVM is the standard sur-
gical method for the anatomical restoration of middle
compartment Stage II–III prolapse; however, it should
be supplemented with a mid-urethral sling to achieve
better SUI treatment. Moreover, the combined mesh and
sling operations yield unfavorably more frequent compli-
cation rates and may provoke voiding dysfunction and
recurrent UTI. Furthermore, following the original
TVM, some residual SUI can develop because of the
backward dislocation of the mesh.
To the best of our knowledge, the present study is the
first to investigate a surgical modification to TVM for
more effective anti-incontinence. Should this newly de-
veloped modification be proved successful in treating
SUI, it could be introduced in clinical practice due to its
simplicity.
Additional files
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